GlaxoSmithKline News

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

May 13 22:54

6-K: Gsk Results of 24th Annual General Meeting

May 9 01:48

6-K: Gsk Board Committee Change

May 9 01:03

6-K: Transaction Notification

May 3 22:46

6-K: Total Voting Rights and Capital

May 1 23:19

6-K: Us Fda Accepts for Priority Review Gsk's Application for an Expanded Indication of Jemperli Plus Chemotherapy to Include All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer

Apr 24 18:48

6-K: Transaction Notification

Apr 19 22:59

6-K: Transaction Notification

Apr 17 22:54

6-K: New Long-Term Data Show Shingrix Continues to Provide High Protection Against Shingles in Adults Aged 50 and over for More Than a Decade

Apr 17 18:14

6-K: Gsk Today Announced Positive Results from the Pivotal Eagle-1 Phase Iii Trial for Gepotidacin

Apr 17 18:09

6-K: The Following Amendments Have Been Made in Accordance with the “director/Pdmr Shareholdings” Announcement Issued by Rns No 6709k

Apr 16 21:55

6-K: GSK's 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA

Apr 16 18:24

GlaxoSmithKline | 6-K: Transaction Notification

Apr 15 23:29

GlaxoSmithKline | 6-K/A: Total Voting Rights and Capital

Apr 4 19:50

GlaxoSmithKline | 6-K: Total Voting Rights and Capital

Apr 3 01:20

GlaxoSmithKline | 6-K: Transaction Notification

Mar 26 19:49

GlaxoSmithKline | 6-K: GlaxoSmithKline releases notice of 2024 Annual General Meeting of Shareholders

Mar 25 21:43

GlaxoSmithKline | 6-K: Transfer of Treasury Shares

Mar 23 00:52

GlaxoSmithKline | 6-K: Transaction Notification

Mar 23 00:22

GlaxoSmithKline | 6-K: Positive Ruby Phase Iii Data Show Potential for Jemperli (Dostarlimab) Combinations in More Patients with Primary Advanced or Recurrent Endometrial Cancer

Mar 18 21:59